Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)

por Hua, Xin, Bi, Xi-Wen, Zhao, Jian-Li, Shi, Yan-Xia, Lin, Ying, Wu, Zhi-Yong, Zhang, Yuan-Qi, Zhang, Le-Hong, Zhang, An-Qing, Huang, Heng, Liu, Xin-Mei, Xu, Fei, Guo, Ying, Xia, Wen, Hong, Ruo-Xi, Jiang, Kui-Kui, Xue, Cong, An, Xin, Zhong, Yong-Yi, Wang, Shu-Sen, Huang, Jia-Jia, Yuan, Zhong-Yu
Publicado 2022